Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vimian Group AB (publ) (VIMIAN.ST)
Stockholm, SE
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.65% | -4.17% | -2.13% | +6.84% | -2.96% | -2.71% | -22.99% | -6.57% | -61.89% | -61.89% | -61.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+13.4% ★ Q1'26: +5.6% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+63.5% ★ Q1'26: +123.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+16.8% ★ Q1'26: +16.9% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+15.7% ★ Q1'26: +19.2% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+5.3% ★ Q1'26: +6.2% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+4.2% Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×2.28× Q1'26: 1.96× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 6 EPS Ana. |
Dec 2029 2 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
173.35M
est: 170.55M (+1.6%)
|
281.31M
est: 282.86M (-0.5%)
|
331.73M
est: 30.15M (+1,000.3%)
|
374.80M
est: 368.59M (+1.7%)
|
425.00M
est: 423.95M (+0.2%)
|
469.53M
463.81M – 476.86M
+10.8% YoY
|
515.11M
507.60M – 527.43M
+9.7% YoY
|
561.88M
554.33M – 573.10M
+9.1% YoY
|
604.44M
596.32M – 616.51M
+7.6% YoY
|
| EBITDA |
36.17M
est: 42.66M (-15.2%)
|
39.20M
est: 70.74M (-44.6%)
|
69.19M
est: 9.56M (+623.6%)
|
82.80M
est: 116.89M (-29.2%)
|
104.70M
est: 134.45M (-22.1%)
|
148.90M
147.09M – 151.23M
+10.8% YoY
|
163.36M
160.98M – 167.27M
+9.7% YoY
|
178.19M
175.80M – 181.75M
+9.1% YoY
|
191.69M
189.11M – 195.52M
+7.6% YoY
|
| EBIT |
19.48M
est: 28.60M (-31.9%)
|
11.98M
est: 47.43M (-74.8%)
|
43.31M
est: 7.16M (+504.6%)
|
49.10M
est: 87.57M (-43.9%)
|
66.60M
est: 100.73M (-33.9%)
|
111.56M
110.20M – 113.30M
+10.8% YoY
|
122.38M
120.60M – 125.31M
+9.7% YoY
|
133.50M
131.70M – 136.16M
+9.1% YoY
|
143.61M
141.68M – 146.48M
+7.6% YoY
|
| Net Income |
6.59M
est: 43.44M (-84.8%)
|
-7.20M
est: 50.67M (-114.2%)
|
9.84M
est: 978.3K (+905.9%)
|
18.50M
est: 35.30M (-47.6%)
|
31.30M
est: 43.34M (-27.8%)
|
58.77M
45.99M – 71.55M
+35.6% YoY
|
69.51M
56.64M – 82.38M
+18.3% YoY
|
75.57M
61.58M – 89.57M
+8.7% YoY
|
94.38M
92.73M – 96.83M
+24.9% YoY
|
| SGA |
41.88M
est: 36.53M (+14.6%)
|
56.93M
est: 60.59M (-6.0%)
|
153.91M
est: 5.47M (+2,711.6%)
|
—
est: 66.93M (-100.0%)
|
—
est: 76.98M (-100.0%)
|
85.26M
84.22M – 86.59M
+10.8% YoY
|
93.53M
92.17M – 95.77M
+9.7% YoY
|
102.03M
100.66M – 104.06M
+9.1% YoY
|
109.76M
108.28M – 111.95M
+7.6% YoY
|
| EPS |
0.02
est: 0.09 (-76.8%)
|
-0.02
est: 0.10 (-117.9%)
|
0.02
est: 0.00 (+979.3%)
|
0.04
est: 0.07 (-45.1%)
|
0.06
est: 0.08 (-26.9%)
|
0.11
0.09 – 0.14
+29.6% YoY
|
0.13
0.11 – 0.16
+21.4% YoY
|
0.15
0.12 – 0.17
+16.6% YoY
|
0.18
0.18 – 0.18
+19.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.09% | 299.8K | 0.23% |
| 2 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.09% | 299.8K | 0.23% |
| 3 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.04% | 1.49M | 0.30% |
| 4 | iShares MSCI Europe Small-Cap ETF IEUS | 0.04% | 66.5K | 0.41% |
| 5 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 246.4K | 0.40% |
| 6 | iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE | 0.03% | 120.8K | 0.10% |
| 7 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.02% | 181.8K | 0.23% |
| 8 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.02% | 181.7K | 0.23% |
| 9 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 1.16M | 0.06% |
| 10 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 37.7K | 0.83% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carl-Johan Zetterberg Boudrie | Deputy CEO, CFO & Interim Head of Specialty Pharma | 560.0K | male |
| Alireza Tajbakhsh | Group CEO & Interim Head of MedTech | 174.0K | male |
| Carl-Johan Ehn | General Counsel | — | male |
| Lotta Lundaas | Head of MedTech | — | female |
| Magnus Kjellberg | Chief Executive Officer of Nextmune | — | male |
| Maria Dahllof Tullberg | Head of IR, Communications & Sustainability | — | female |
| Martin Bengtson | Head of M&A | — | male |
| Michael Thunell | Head of Veterinary Services | — | — |
| Stefano Santarelli | Chief Executive Officer of Indical Bioscience | — | male |
| Bart Bremer | Chief People Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIMIAN.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
